Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$41.28-0.3%$47.24$38.91▼$147.03$1.19B0.73959,034 shs559,882 shsTNDMTandem Diabetes Care$15.40-7.7%$17.59$9.98▼$29.65$1.14B1.582.55 million shs2.10 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-0.29%-2.26%-1.24%-24.70%-67.53%TNDMTandem Diabetes Care-7.73%-5.11%+13.82%-37.47%-23.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$41.28-0.3%$47.24$38.91▼$147.03$1.19B0.73959,034 shs559,882 shsTNDMTandem Diabetes Care$15.40-7.7%$17.59$9.98▼$29.65$1.14B1.582.55 million shs2.10 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-0.29%-2.26%-1.24%-24.70%-67.53%TNDMTandem Diabetes Care-7.73%-5.11%+13.82%-37.47%-23.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.10Hold$81.8498.28% UpsideTNDMTandem Diabetes Care 2.48Hold$29.8493.78% UpsideCurrent Analyst Ratings BreakdownLatest TNDM and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026INSPInspire Medical Systems OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/15/2026INSPInspire Medical Systems Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSector Perform ➝ Buy6/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/10/2026TNDMTandem Diabetes Care Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/1/2026TNDMTandem Diabetes Care Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Overweight$21.00 ➝ $27.005/28/2026TNDMTandem Diabetes Care CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$22.00 ➝ $17.005/27/2026TNDMTandem Diabetes Care The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/26/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026INSPInspire Medical Systems Summit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/22/2026INSPInspire Medical Systems Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Underperform$39.005/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$911.98M1.30$2.86 per share14.45$26.88 per share1.54TNDMTandem Diabetes Care$1.01B1.04N/AN/A$2.29 per share6.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$145.42M$4.499.1928.474.2714.33%10.35%8.81%8/3/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/A385.00N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest TNDM and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.344.48TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.20%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,33328.81 million28.18 millionOptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableTNDM and INSP HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 10, 2026 | americanbankingnews.comTandem Diabetes: Neutral Stance Maintained as Mobi Tubeless Opportunity Balances Execution Risks; $25 Price Target UnchangedJune 9, 2026 | tipranks.comTandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comHow The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst TargetsJune 7, 2026 | finance.yahoo.comTandem insulin pumps cleared in EU for expanded indicationsJune 6, 2026 | seekingalpha.comWall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?June 5, 2026 | zacks.comTandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During PregnancyJune 5, 2026 | businesswire.comReasons to Add Tandem Diabetes Stock to Your Portfolio Right NowJune 4, 2026 | zacks.com3 Stocks to Invest in as Broker Rating Upgrades Signal UpsideJune 4, 2026 | zacks.comTandem: Upgrading To Hold On A High-Stakes Pivot StoryJune 4, 2026 | seekingalpha.comWells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump ShiftJune 3, 2026 | finance.yahoo.comTandem Diabetes Valuation: Is 1.1x Sales a Buy?June 3, 2026 | zacks.comTNDM Stock: What to Know About Tandem's 2026 ResetJune 2, 2026 | zacks.comTandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells InvestorsMay 28, 2026 | gurufocus.comTandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?May 24, 2026 | finance.yahoo.comSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19, 2026 | zacks.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNDM and INSP Company DescriptionsInspire Medical Systems NYSE:INSP$41.28 -0.12 (-0.28%) Closing price 06/17/2026 03:59 PM EasternExtended Trading$41.20 -0.07 (-0.18%) As of 06/17/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Tandem Diabetes Care NASDAQ:TNDM$15.40 -1.29 (-7.73%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$15.92 +0.52 (+3.36%) As of 06/17/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
